^
    Back
    Association details:
    Biomarker:GNAQ G48L + FGFR4 C172G
    Cancer:Uveal Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Int J Mol Sci
    Title:

    Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

    Published date:
    10/28/2020
    Excerpt:
    We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to MEK inhibition...we also found an FGFR4 p.Cys172Gly mutation...Based on these analyses, the patient received the MEK inhibitor trametinib with a lasting clinical benefit.
    DOI:
    10.3390/ijms21218021